Ustekinumab for the treatment of psoriatic arthritis: An update

Parastoo Davari; Michael S. Leo; Faranak Kamangar; Nasim Fazel

doi:10.2147/CCID.S50003

Ustekinumab for the treatment of psoriatic arthritis: An update

Parastoo Davari, Michael S. Leo, Faranak Kamangar, Nasim Fazel

Dermatology

Research output: Contribution to journal › Article

9 Scopus citations

Abstract

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

Original language	English (US)
Pages (from-to)	243-249
Number of pages	7
Journal	Clinical, Cosmetic and Investigational Dermatology
Volume	7
DOIs	https://doi.org/10.2147/CCID.S50003
State	Published - Sep 2 2014

Keywords

Psoriasis
Psoriatic arthritis
Ustekinumab

ASJC Scopus subject areas

Dermatology

Access to Document

10.2147/CCID.S50003

Fingerprint Dive into the research topics of 'Ustekinumab for the treatment of psoriatic arthritis: An update'. Together they form a unique fingerprint.

Cite this

Davari, P., Leo, M. S., Kamangar, F., & Fazel, N. (2014). Ustekinumab for the treatment of psoriatic arthritis: An update. Clinical, Cosmetic and Investigational Dermatology, 7, 243-249. https://doi.org/10.2147/CCID.S50003

@article{fa2e768b0e244eddb7c160787475eb79,

title = "Ustekinumab for the treatment of psoriatic arthritis: An update",

abstract = "Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.",

keywords = "Psoriasis, Psoriatic arthritis, Ustekinumab",

author = "Parastoo Davari and Leo, {Michael S.} and Faranak Kamangar and Nasim Fazel",

year = "2014",

month = sep,

day = "2",

doi = "10.2147/CCID.S50003",

language = "English (US)",

volume = "7",

pages = "243--249",

journal = "Clinical, Cosmetic and Investigational Dermatology",

issn = "1178-7015",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ustekinumab for the treatment of psoriatic arthritis

T2 - An update

AU - Davari, Parastoo

AU - Leo, Michael S.

AU - Kamangar, Faranak

AU - Fazel, Nasim

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

AB - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

KW - Psoriasis

KW - Psoriatic arthritis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84907879772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907879772&partnerID=8YFLogxK

U2 - 10.2147/CCID.S50003

DO - 10.2147/CCID.S50003

M3 - Article

AN - SCOPUS:84907879772

VL - 7

SP - 243

EP - 249

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -